[Remote] Director, Clinical Pharmacology at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, BiologicsIndustries

Skills

Key technologies and capabilities for this role

Clinical PharmacologyDrug DevelopmentQuantitative PharmacologyImmunologyInflammationStrategic PlanningBiologicsAntibody Engineering

Questions & Answers

Common questions about this position

What is the salary or compensation for the Director, Clinical Pharmacology role?

This information is not specified in the job description.

Is this Director, Clinical Pharmacology position remote or does it require office work?

This information is not specified in the job description.

What key skills are required for the Director, Clinical Pharmacology role?

The role requires expertise in leading Clinical Pharmacology/PK/PD activities, strong communication skills to present to teams and leaders, and the ability to collaborate with cross-functional teams including preclinical, clinical development, and regulatory affairs.

What is the company culture like at Apogee Therapeutics?

Apogee Therapeutics is a fast-paced, highly dynamic environment committed to building an exceptional company culture founded on C.O.R.E. values: Caring, Original, Resilient, and Egoless, where employees can shape the culture and grow professionally.

What makes a strong candidate for the Director, Clinical Pharmacology position?

A strong candidate is motivated with expertise in clinical pharmacology for immunology and inflammation, experience leading PK/PD strategies from first-in-human to approval, and the ability to collaborate cross-functionally while influencing key decisions.

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free